The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of venetoclax-based treatment for patients with Richter’s syndrome
Paul Hampel, MD, Mayo Clinic, Rochester, MN, discusses the safety and efficacy of venetoclax-based treatment for patients with Richter’s syndrome. Dr Hampel first provides some background information on Richter’s syndrome and the poor outcomes associated with these patients, and then further discusses the promising activity observed with a variety of venetoclax-based regimens. Following this, Dr Hampel highlights the safety profile of these combinations and the importance of further investigating their efficacy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
